LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

219.92 -0.04

Buy Sell

Overview

Share price change

24h

Current

Min

217.21

Max

224.37

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.99% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-178M 13B
Previous open	219.96
Previous close	219.92

News Sentiment

By Acuity

54%

46%

285 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 mar 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar 2026, 23:36 UTC

Market Talk

Major News Events

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar 2026, 23:35 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar 2026, 23:29 UTC

Earnings

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

32.99% upside

12 Months Forecast

Average 293.77 USD 32.99%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

285 / 350 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.